Aegis Sciences Corporation Unveils NPS Testing Updates
Aegis Sciences Corporation, a prominent health care testing laboratory, is excited to announce significant updates to their novel psychoactive substance (NPS) testing menu. This development is part of their commitment to benefiting healthcare practices by integrating the latest findings and recommendations in the field.
Collaboration with Experts
Aegis enhances its testing capabilities by regularly updating its offerings, a process guided by collaborative efforts with the Center for Forensic Science Research and Education (CFSRE) and the Society of Forensic Toxicologist (SOFT) NPS Committee. Their innovations reflect the evolving challenges of substance detection and address the emergence of new psychoactive substances. These updates include the latest CFSRE’s tier one and tier two scope recommendations, aimed at providing the most relevant testing solutions.
Commitment to Drug Trend Reflection
Dr. Rebecca Heltsley, Senior Vice President of Research and Development at Aegis, highlighted the company’s focus on developing precise analytical methods for identifying new compounds that are indicative of real-world drug use patterns. This continuous improvement reflects a dedication to keeping pace with the changing landscape of substances in circulation. Aegis’s approach ensures that practitioners stay informed about high-risk substances, providing vital tools for addressing the urgent needs of their communities.
New Additions to the Testing Menu
Notable updates to the NPS testing menu include the addition of o/m/p-Methylfentanyl, known to have increased prevalence in illicit markets, N-Isopropyl Butylone, linked with methamphetamine, and phenylbutazone, a previously withdrawn anti-inflammatory drug now appearing as an adulterant. According to Dr. Josh Schrecker, Senior Director of Clinical Affairs at Aegis, these updates empower clinicians to refine their harm reduction strategies effectively and enhance overdose prevention initiatives.
Enhanced Tools for Clients
“This update is tangible proof of our commitment,” stated Dr. Frank Basile, CEO of Aegis Sciences Corporation. He emphasized the importance of providing clients with robust tools to understand the illicit substances affecting their communities and manage related risks effectively. This solidified approach aims to create a safer environment through informed decisions based on comprehensive substance analysis.
Exploring Testing Options
Healthcare practitioners looking for more information about Aegis's updated NPS testing offerings are encouraged to visit their comprehensive online resources. The website provides detailed insights into their innovative solutions, including the capabilities of their latest testing methodologies.
About Aegis Sciences Corporation
Founded in 1990, Aegis Sciences Corporation stands out as a laboratory sciences company dedicated to providing exceptional, science-driven testing and consulting services. Their clientele includes healthcare providers, pharmaceutical companies, sports organizations, respected athletic programs, Fortune 500 companies, and government entities across the nation. For those interested in learning more about Aegis's extensive services and expertise, visiting their official website is highly recommended.
Frequently Asked Questions
What is the focus of the updates to the NPS testing menu?
The updates focus on incorporating new psychoactive substances that reflect current drug use trends, ensuring healthcare practitioners have access to the latest substance analysis tools.
How does Aegis Sciences Corporation ensure relevancy in their testing?
Aegis collaborates with industry experts, like the CFSRE and SOFT, to ensure their testing methods align with current recommendations and practices.
What new substances have been added to the testing menu?
Recent additions include o/m/p-Methylfentanyl, N-Isopropyl Butylone, and phenylbutazone, which address emerging risks in illicit substances.
How can healthcare practitioners access more information?
Practitioners can explore the updated offerings through Aegis’s official website, which provides detailed resources on their testing capabilities.
What commitment does Aegis make to its clients?
Aegis is committed to providing clients with the best tools to understand illicit substances affecting their communities, enabling informed risk management.